Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies

Oliver Brunckhorst; Safiya Hashemi; Anastasia Martin; Gincy George; Mieke Van Hemelrijck; Prokar Dasgupta; Robert Stewart; Kamran Ahmed

doi:10.1038/s41391-020-00286-0

Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies

Oliver Brunckhorst, Safiya Hashemi, Anastasia Martin, Gincy George, Mieke Van Hemelrijck, Prokar Dasgupta, Robert Stewart, Kamran Ahmed

MRC Centre for Transplantation, Guy's Hospital, King's College London, England, SE1 1UL, UK.

Research output: Contribution to journal › Review article › peer-review

61 Citations (Scopus)

Abstract

Background: Psychiatric implications of prostate cancer are increasingly recognised, having important effects on oncological and functional outcomes. However, findings for co-occurring depression, anxiety, and suicidality remain variable. Therefore, this review of observational studies aimed to establish best estimates of the prevalence and rates of these outcomes in prostate cancer patients. Methods: A systematic literature search was conducted using MEDLINE, Scopus, PsycInfo, and Cochrane Library databases from inception up to 26 May 2020. Observational studies using validated methods for evaluating prevalences of depression, anxiety and suicidal ideation, or suicide mortality rates post prostate cancer diagnosis were included. Random effect models were used to calculate pooled prevalences of depressive and anxiety symptoms or disorders, and suicidal ideation post diagnosis. Additionally, pooled crude suicide mortality rates per 100,000 person years were calculated. Heterogeneity was explored using a stratified analysis. Results: Of 3537 articles screened, 117 were included. Pooled prevalence for depressive disorders was 5.81% (95% CI 4.36–7.46) in 11 studies, representing 655,149 patients. Significant depressive symptoms were identified in 17.07% (15.14–19.09) across 32,339 patients and 76 studies. In total, 16.86% (14.92–18.89) had significant anxiety symptoms in 56 studies combining 24,526 patients. In 6,173 patients and eight studies, recent suicidal ideation was present in 9.85% (7.31–12.70). Crude suicide mortality rate after diagnosis was 47.1 (39.85–54.96) per 100,000 person years in 12 studies. Significant heterogeneity was seen with potential sources identified through our sensitivity analysis including diagnostic method utilised, study size and location of study. Conclusions: The mental health impact in patients with prostate cancer is significant. Depressive, anxiety, and suicidal symptoms were common. Additionally, a high suicide mortality rate was identified when compared to general population estimates. Screening of patients and integration of physical and mental health care should be evaluated further to improve quality of life and functional outcomes.

Original language	English
Pages (from-to)	281–289
Number of pages	9
Journal	PROSTATE CANCER AND PROSTATIC DISEASES
Volume	24
Issue number	2
Early online date	25 Sept 2020
DOIs	https://doi.org/10.1038/s41391-020-00286-0
Publication status	Published - 21 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41391-020-00286-0

Cite this

@article{819041a8eced4c23b7517571ab9c9126,

title = "Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies",

abstract = "Background: Psychiatric implications of prostate cancer are increasingly recognised, having important effects on oncological and functional outcomes. However, findings for co-occurring depression, anxiety, and suicidality remain variable. Therefore, this review of observational studies aimed to establish best estimates of the prevalence and rates of these outcomes in prostate cancer patients. Methods: A systematic literature search was conducted using MEDLINE, Scopus, PsycInfo, and Cochrane Library databases from inception up to 26 May 2020. Observational studies using validated methods for evaluating prevalences of depression, anxiety and suicidal ideation, or suicide mortality rates post prostate cancer diagnosis were included. Random effect models were used to calculate pooled prevalences of depressive and anxiety symptoms or disorders, and suicidal ideation post diagnosis. Additionally, pooled crude suicide mortality rates per 100,000 person years were calculated. Heterogeneity was explored using a stratified analysis. Results: Of 3537 articles screened, 117 were included. Pooled prevalence for depressive disorders was 5.81% (95% CI 4.36–7.46) in 11 studies, representing 655,149 patients. Significant depressive symptoms were identified in 17.07% (15.14–19.09) across 32,339 patients and 76 studies. In total, 16.86% (14.92–18.89) had significant anxiety symptoms in 56 studies combining 24,526 patients. In 6,173 patients and eight studies, recent suicidal ideation was present in 9.85% (7.31–12.70). Crude suicide mortality rate after diagnosis was 47.1 (39.85–54.96) per 100,000 person years in 12 studies. Significant heterogeneity was seen with potential sources identified through our sensitivity analysis including diagnostic method utilised, study size and location of study. Conclusions: The mental health impact in patients with prostate cancer is significant. Depressive, anxiety, and suicidal symptoms were common. Additionally, a high suicide mortality rate was identified when compared to general population estimates. Screening of patients and integration of physical and mental health care should be evaluated further to improve quality of life and functional outcomes.",

author = "Oliver Brunckhorst and Safiya Hashemi and Anastasia Martin and Gincy George and {Van Hemelrijck}, Mieke and Prokar Dasgupta and Robert Stewart and Kamran Ahmed",

note = "Funding Information: Acknowledgements OB, PD, and KA acknowledge research support from the Medical Research Council (MRC) Centre for Transplantation and funding from the King{\textquoteright}s Medical Research Trust (KMRT). PD further acknowledges funding from the King{\textquoteright}s College London-Vattikuti Institute of Robotic Surgery and the Guy{\textquoteright}s and St. Thomas{\textquoteright} (GSTT) Charity. KA further acknowledges funding from the Royal College of Surgeons of England, The Urology Foundation, Coptcoat Charity and the Pelican Foundation. RS is part-funded by: (1) the National Institute for Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London; (2) a MRC Mental Health Data Pathfinder Award to King{\textquoteright}s College London; (3) an NIHR Senior Investigator Award; (4) the NIHR Applied Research Collaboration South London (NIHR ARC South London) at King{\textquoteright}s College Hospital NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = may,

day = "21",

doi = "10.1038/s41391-020-00286-0",

language = "English",

volume = "24",

pages = "281–289",

journal = "PROSTATE CANCER AND PROSTATIC DISEASES",

issn = "1365-7852",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies

AU - Brunckhorst, Oliver

AU - Hashemi, Safiya

AU - Martin, Anastasia

AU - George, Gincy

AU - Van Hemelrijck, Mieke

AU - Dasgupta, Prokar

AU - Stewart, Robert

AU - Ahmed, Kamran

N1 - Funding Information: Acknowledgements OB, PD, and KA acknowledge research support from the Medical Research Council (MRC) Centre for Transplantation and funding from the King’s Medical Research Trust (KMRT). PD further acknowledges funding from the King’s College London-Vattikuti Institute of Robotic Surgery and the Guy’s and St. Thomas’ (GSTT) Charity. KA further acknowledges funding from the Royal College of Surgeons of England, The Urology Foundation, Coptcoat Charity and the Pelican Foundation. RS is part-funded by: (1) the National Institute for Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King’s College London; (2) a MRC Mental Health Data Pathfinder Award to King’s College London; (3) an NIHR Senior Investigator Award; (4) the NIHR Applied Research Collaboration South London (NIHR ARC South London) at King’s College Hospital NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Publisher Copyright: © 2020, The Author(s), under exclusive licence to Springer Nature Limited. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/5/21

Y1 - 2021/5/21

N2 - Background: Psychiatric implications of prostate cancer are increasingly recognised, having important effects on oncological and functional outcomes. However, findings for co-occurring depression, anxiety, and suicidality remain variable. Therefore, this review of observational studies aimed to establish best estimates of the prevalence and rates of these outcomes in prostate cancer patients. Methods: A systematic literature search was conducted using MEDLINE, Scopus, PsycInfo, and Cochrane Library databases from inception up to 26 May 2020. Observational studies using validated methods for evaluating prevalences of depression, anxiety and suicidal ideation, or suicide mortality rates post prostate cancer diagnosis were included. Random effect models were used to calculate pooled prevalences of depressive and anxiety symptoms or disorders, and suicidal ideation post diagnosis. Additionally, pooled crude suicide mortality rates per 100,000 person years were calculated. Heterogeneity was explored using a stratified analysis. Results: Of 3537 articles screened, 117 were included. Pooled prevalence for depressive disorders was 5.81% (95% CI 4.36–7.46) in 11 studies, representing 655,149 patients. Significant depressive symptoms were identified in 17.07% (15.14–19.09) across 32,339 patients and 76 studies. In total, 16.86% (14.92–18.89) had significant anxiety symptoms in 56 studies combining 24,526 patients. In 6,173 patients and eight studies, recent suicidal ideation was present in 9.85% (7.31–12.70). Crude suicide mortality rate after diagnosis was 47.1 (39.85–54.96) per 100,000 person years in 12 studies. Significant heterogeneity was seen with potential sources identified through our sensitivity analysis including diagnostic method utilised, study size and location of study. Conclusions: The mental health impact in patients with prostate cancer is significant. Depressive, anxiety, and suicidal symptoms were common. Additionally, a high suicide mortality rate was identified when compared to general population estimates. Screening of patients and integration of physical and mental health care should be evaluated further to improve quality of life and functional outcomes.

AB - Background: Psychiatric implications of prostate cancer are increasingly recognised, having important effects on oncological and functional outcomes. However, findings for co-occurring depression, anxiety, and suicidality remain variable. Therefore, this review of observational studies aimed to establish best estimates of the prevalence and rates of these outcomes in prostate cancer patients. Methods: A systematic literature search was conducted using MEDLINE, Scopus, PsycInfo, and Cochrane Library databases from inception up to 26 May 2020. Observational studies using validated methods for evaluating prevalences of depression, anxiety and suicidal ideation, or suicide mortality rates post prostate cancer diagnosis were included. Random effect models were used to calculate pooled prevalences of depressive and anxiety symptoms or disorders, and suicidal ideation post diagnosis. Additionally, pooled crude suicide mortality rates per 100,000 person years were calculated. Heterogeneity was explored using a stratified analysis. Results: Of 3537 articles screened, 117 were included. Pooled prevalence for depressive disorders was 5.81% (95% CI 4.36–7.46) in 11 studies, representing 655,149 patients. Significant depressive symptoms were identified in 17.07% (15.14–19.09) across 32,339 patients and 76 studies. In total, 16.86% (14.92–18.89) had significant anxiety symptoms in 56 studies combining 24,526 patients. In 6,173 patients and eight studies, recent suicidal ideation was present in 9.85% (7.31–12.70). Crude suicide mortality rate after diagnosis was 47.1 (39.85–54.96) per 100,000 person years in 12 studies. Significant heterogeneity was seen with potential sources identified through our sensitivity analysis including diagnostic method utilised, study size and location of study. Conclusions: The mental health impact in patients with prostate cancer is significant. Depressive, anxiety, and suicidal symptoms were common. Additionally, a high suicide mortality rate was identified when compared to general population estimates. Screening of patients and integration of physical and mental health care should be evaluated further to improve quality of life and functional outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85091509195&partnerID=8YFLogxK

U2 - 10.1038/s41391-020-00286-0

DO - 10.1038/s41391-020-00286-0

M3 - Review article

SN - 1365-7852

VL - 24

SP - 281

EP - 289

JO - PROSTATE CANCER AND PROSTATIC DISEASES

JF - PROSTATE CANCER AND PROSTATIC DISEASES

IS - 2

ER -

Depression, Anxiety and Suicidality in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this